Literature DB >> 18644985

WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression.

Debra J Morrison1, Marianne K H Kim, Windy Berkofsky-Fessler, Jonathan D Licht.   

Abstract

In its role as a tumor suppressor, WT1 transactivates several genes that are regulators of cell growth and differentiation pathways. For instance, WT1 induces the expression of the cell cycle regulator p21, the growth-regulating glycoprotein amphiregulin, the proapoptotic gene Bak, and the Ras/mitogen-activated protein kinase (MAPK) inhibitor Sprouty1. Here, we show that WT1 transactivates another important negative regulator of the Ras/MAPK pathway, MAPK phosphatase 3 (MKP3). In a WT1-inducible cell line that exhibits decreased cell growth and increased apoptosis on expression of WT1, microarray analysis showed that MKP3 is the most highly induced gene. This was confirmed by real-time PCR where MKP3 and other members of the fibroblast growth factor 8 syn expression group, which includes Sprouty 1 and the Ets family of transcription factors, were induced rapidly following WT1 expression. WT1 induction was associated with a block in the phosphorylation of extracellular signal-regulated kinase in response to epidermal growth factor stimulation, an effect mediated by MKP3. In the presence of a dominant-negative MKP3, WT1 could no longer block phosphorylation of extracellular signal-regulated kinase. Lastly, when MKP3 expression is down-regulated by short hairpin RNA, WT1 is less able to block Ras-mediated transformation of 3T3 cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644985      PMCID: PMC2587040          DOI: 10.1158/1541-7786.MCR-08-0078

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  49 in total

1.  Physical and functional interaction between WT1 and p53 proteins.

Authors:  S Maheswaran; S Park; A Bernard; J F Morris; F J Rauscher; D E Hill; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

2.  WT1 activates a glomerular-specific enhancer identified from the human nephrin gene.

Authors:  Gordon Guo; Debra J Morrison; Jonathan D Licht; Susan E Quaggin
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

3.  Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal.

Authors:  Maria Karlsson; Joanne Mathers; Robin J Dickinson; Margret Mandl; Stephen M Keyse
Journal:  J Biol Chem       Date:  2004-07-21       Impact factor: 5.157

4.  Inducible expression of a MAP kinase phosphatase-3-GFP chimera specifically blunts fibroblast growth and ras-dependent tumor formation in nude mice.

Authors:  S Marchetti; C Gimond; D Roux; E Gothié; J Pouysségur; Gilles Pagès
Journal:  J Cell Physiol       Date:  2004-06       Impact factor: 6.384

5.  MKP3 mediates the cellular response to FGF8 signalling in the vertebrate limb.

Authors:  Yasuhiko Kawakami; Joaquín Rodríguez-León; Christopher M Koth; Dirk Büscher; Tohru Itoh; Angel Raya; Jennifer K Ng; Concepción Rodríguez Esteban; Shigeru Takahashi; Domingos Henrique; May-Fun Schwarz; Hiroshi Asahara; Juan Carlos Izpisúa Belmonte
Journal:  Nat Cell Biol       Date:  2003-06       Impact factor: 28.824

6.  Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras.

Authors:  Janel K Warmka; Laura J Mauro; Elizabeth V Wattenberg
Journal:  J Biol Chem       Date:  2004-05-24       Impact factor: 5.157

7.  The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.

Authors:  S Maheswaran; C Englert; P Bennett; G Heinrich; D A Haber
Journal:  Genes Dev       Date:  1995-09-01       Impact factor: 11.361

8.  The tumor suppressor gene WT1 inhibits ras-mediated transformation.

Authors:  X N Luo; J C Reddy; P L Yeyati; A H Idris; S Hosono; D A Haber; J D Licht; G F Atweh
Journal:  Oncogene       Date:  1995-08-17       Impact factor: 9.867

9.  WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.

Authors:  C Englert; X Hou; S Maheswaran; P Bennett; C Ngwu; G G Re; A J Garvin; M R Rosner; D A Haber
Journal:  EMBO J       Date:  1995-10-02       Impact factor: 11.598

10.  Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation.

Authors:  Jamie A Davies; Michael Ladomery; Peter Hohenstein; Lydia Michael; Anna Shafe; Lee Spraggon; Nick Hastie
Journal:  Hum Mol Genet       Date:  2003-11-25       Impact factor: 6.150

View more
  9 in total

1.  Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.

Authors:  Silvestre Vicent; Ron Chen; Leanne C Sayles; Chenwei Lin; Randal G Walker; Anna K Gillespie; Aravind Subramanian; Gregory Hinkle; Xiaoping Yang; Sakina Saif; David E Root; Vicki Huff; William C Hahn; E Alejandro Sweet-Cordero
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

2.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

3.  Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.

Authors:  Kai-Min Lin; Sue-Jane Lin; Juin-Han Lin; Pei-Yi Lin; Pu-Lin Teng; Hsueh-Erh Wu; Te-Huei Yeh; Ying-Piao Wang; Mei-Ru Chen; Ching-Hwa Tsai
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

4.  Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.

Authors:  Maike Busch; Heinrich Schwindt; Artur Brandt; Manfred Beier; Nicole Görldt; Paul Romaniuk; Eneda Toska; Stefan Roberts; Hans-Dieter Royer; Brigitte Royer-Pokora
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

Review 5.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

Review 6.  Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1).

Authors:  Eneda Toska; Stefan G E Roberts
Journal:  Biochem J       Date:  2014-07-01       Impact factor: 3.857

7.  SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability.

Authors:  Glenn M Marshall; Pei Y Liu; Samuele Gherardi; Christopher J Scarlett; Antonio Bedalov; Ning Xu; Nuncio Iraci; Emanuele Valli; Dora Ling; Wayne Thomas; Margo van Bekkum; Eric Sekyere; Kacper Jankowski; Toby Trahair; Karen L Mackenzie; Michelle Haber; Murray D Norris; Andrew V Biankin; Giovanni Perini; Tao Liu
Journal:  PLoS Genet       Date:  2011-06-16       Impact factor: 5.917

8.  A systematic analysis of genetic interactions and their underlying biology in childhood cancer.

Authors:  Josephine T Daub; Saman Amini; Denise J E Kersjes; Xiaotu Ma; Natalie Jäger; Jinghui Zhang; Stefan M Pfister; Frank C P Holstege; Patrick Kemmeren
Journal:  Commun Biol       Date:  2021-10-06

9.  Wilms' tumor 1 (WT1) promotes ovarian cancer progression by regulating E-cadherin and ERK1/2 signaling.

Authors:  Yun Han; Chao Song; Tingting Zhang; Qianqian Zhou; Xiaoqian Zhang; Jing Wang; Boqun Xu; Xuesen Zhang; Xiaoqiu Liu; Xiaoyan Ying
Journal:  Cell Cycle       Date:  2020-09-07       Impact factor: 4.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.